Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$52.73 USD
-3.65 (-6.47%)
Updated Jun 11, 2024 04:00 PM ET
Pre-Market: $53.81 +1.08 (2.05%) 8:52 AM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
VKTX 52.73 -3.65(-6.47%)
Will VKTX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for VKTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VKTX
Viking Therapeutics, Inc. (VKTX) Advances While Market Declines: Some Information for Investors
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates
VKTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
Here's Why Viking Therapeutics, Inc. (VKTX) Gained But Lagged the Market Today
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
Other News for VKTX
Profiting from the Crowd: 3 Stocks Set to Surge on Retail Investor Enthusiasm
10 Health Care Stocks With Whale Alerts In Today's Session
Viking Therapeutics: MASH Data Punished By Wall Street Amid GLP-1 Uncertainty
Biotech Alert: Searches spiking for these stocks today
Buy Rating on Viking Therapeutics: Promising Phase 2b Results and Strong Safety Profile for NASH Candidate VK2809